Related Experiment Video
Updated: Mar 27, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma
Catherine Besner Morin1, David Roberge2, Irina Turchin3
1McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada Université de Montréal, Montreal, QC, Canada.
Background:
Numerous treatments are available for cutaneous T-cell lymphoma (CTCL), including systemic retinoids. Very few data are available on topical retinoids.
Objectives:
The aim of this study was to evaluate the safety and efficiency of tazarotene as monotherapy for early-stage CTCL.
Methods:
An open-label, prospective study of tazarotene as monotherapy for stages IA to IIA CTCL was conducted. Index lesions on 10 patients were followed for 6 months on treatment, plus at least 6 months off treatment.
Results:
Six patients (60%) showed complete response (CR). Erythema, scaling, thickness, and lesion area decreased progressively throughout treatment. The mean time to CR was 3.8 months; CR was durable for at least 6 months in 83%. Of the 4 patients (40%) without CR, 2 (20%) had stable disease and 2 (20%) stopped the medication because of local side effects; none showed progression.
Conclusions:
This is the first Canadian trial providing evidence that topical tazarotene has excellent potential as a monotherapy agent for stages I to IIA CTCL.
More Related Videos
Related Concept Videos
Acne Infection
Tumor Immunotherapy
Treatment Resistent Cancers
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
